Natco Pharma Ltd. — Investor Relations & Filings
Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Disclosure under SEBI Takeover Regulations | 2026-04-29 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | |
| Trading Window | 2026-03-31 | English | |
| Shareholders meeting | 2026-03-25 | English | |
| Outcome of Board Meeting | 2026-03-24 | English | |
| Press Release | 2026-03-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42187393 | Disclosure under SEBI Takeover Regulations | 2026-04-29 | English | ||
| 42174118 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | ||
| 42190499 | Trading Window | 2026-03-31 | English | ||
| 42183610 | Shareholders meeting | 2026-03-25 | English | ||
| 42194221 | Outcome of Board Meeting | 2026-03-24 | English | ||
| 42220287 | Press Release | 2026-03-20 | English | ||
| 43858767 | Board Meeting — Board Meeting Intimation | 2026-03-18 | English | ||
| 43858780 | Board Meeting — Other business matters | 2026-03-18 | English | ||
| 42197773 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-03-06 | English | ||
| 42178518 | Press Release | 2026-03-03 | English | ||
| 42178073 | News Verification | 2026-02-25 | English | ||
| 42195120 | Copy of Newspaper Publication | 2026-02-21 | English | ||
| 42201901 | Shareholders meeting | 2026-02-20 | English | ||
| 42175436 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-18 | English | ||
| 42219592 | Press Release | 2026-02-14 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
Natco Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/62741/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=62741 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=62741 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=62741 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 62741}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Natco Pharma Ltd. (id: 62741)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.